IndustryCompany release

Repligen raises 2026 revenue guidance to $844–852M after closing BioLife Solutions acquisition

🇺🇸 Repligen Corp (RGEN) · Tue 27 Oct 2026

The bioprocessing supplier reported third-quarter sales of $209.3 million, up 11%, and said the BioLife deal extends its reach into cell therapy consumables.

Repligen reported third-quarter 2026 revenue of $209.3 million on 27 October, an increase of 11% on a reported basis and 12.5% organically. The company also raised its full-year revenue guidance to between $844 million and $852 million.

The US bioprocessing supplier closed its acquisition of BioLife Solutions on 6 October. Repligen says the purchase expands its business into consumables for cell therapy.

The quarter included a GAAP operating loss, which the company attributed to an impairment charge on intangible assets. The summary provided does not give the size of the charge or the affected assets.

Separately, Repligen opened a training and innovation centre in Seoul on 23 October. No further details on the facility were available.

What it means for your team

  • Quality and supply-chain teams using Repligen products or BioLife consumables should watch for any changes to supplier agreements, quality documentation or site arrangements after the acquisition; none are described in the available information.
  • Cell therapy developers may see Repligen as a broader single-source supplier, which could prompt a review of supplier qualification and dependency risk.
  • Market-access and procurement staff should note that the raised guidance reflects the company's own outlook, not an independent forecast.

Company's press release (SEC filing): Repligen Corp ↗

Article written by VigiEye from the official source (Repligen Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →